title: Hodgkin's lymphoma in adults: diagnosis, treatment and follow-up.
abstract: BACKGROUND
  With an incidence of 2 to 3 cases per 100 000 persons per year, Hodkgin's lymphoma (HL) is rare, but nonetheless one of the most common cancers in young adults. Improved treatment has made HL curable even in advanced stages, but controversy still surrounds a number of issues in patient care. Current research focuses on the avoidance of long-term adverse effects and secondary malignancies.
  
  
  METHODS
  We selectively searched MEDLINE, CENTRAL, and the Guideline International Network for publications about HL. Two experts independently screened the retrieved publications for pertinence and extracted data from potentially relevant meta-analyses, randomized controlled trials (RCTs), and cohort studies into evidence tables.
  
  
  RESULTS
  32 key questions were answered with 160 recommendations on the basis of evidence from 43 RCTs, 21 meta-analyses, and 119 cohort studies. Patients in an early stage of HL should be treated with two cycles of ABVD followed by involved-field radiotherapy (IF-RT) at a dose of 20 Gy (5-year overall survival [OS]: 94%). Patients in an intermediate (early unfavorable) stage should be treated with two cycles of BEACOPP escalated followed by two cycles of ABVD and 30 Gy IF-RT (5-year OS: 97.2%). Patients in an advanced stage should be treated with six cycles of BEACOPP escalated, and the decision whether this should be followed by consolidating radiotherapy (30 Gy) should be based on the findings of positron-emission tomography (radiate in case of PET-positive residual tumor; 5-year OS: 95.3%). Depending on the treatment regimen, there may be adverse effects including infection, leukopenia, anemia, thrombocytopenia, secondary neoplasia, and fertility disorders.
  
  
  CONCLUSIONS
  Most questions in the treatment of HL can now be answered on the basis of sufficient evidence from the literature. This holds in particular for the potential benefit to be gained from PET, follow-up care, and lifestyle recommendations for patients.
authors.affiliation: Cochrane Haematological Malignancies Group, Department I of Internal Medicine: Haematology, Immunology, Infectiology, Intensive Care and Oncology, University Hospital of Cologne.
authors.forename: Michaela
authors.initials: M
authors.lastname: Rancea
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
authors.forename: Bastian
authors.initials: B
authors.lastname: von Tresckow
authors.forename: Teresa
authors.initials: T
authors.lastname: Halbsguth
authors.forename: Karolin
authors.initials: K
authors.lastname: Behringer
authors.forename: Nicole
authors.initials: N
authors.lastname: Skoetz
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D019317:Evidence-Based Medicine; D005260:Female; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D038622:Internationality; D008297:Male; D008495:Medical Oncology / Q000592:standards*; D017410:Practice Guidelines as Topic; D018714:Radiotherapy, Adjuvant / Q000379:methods*
references.citation: Biol Blood Marrow Transplant. 2008 Aug;14(8):904-12
references.pmid: 18640574
references.citation: Dtsch Arztebl Int. 2012 Mar;109(12):220-6
references.pmid: 22532814
references.citation: Blood. 2008 Nov 15;112(10):3989-94
references.pmid: 18757777
references.citation: J Clin Oncol. 2012 Mar 20;30(9):907-13
references.pmid: 22271480
references.citation: Cancer. 2007 Dec 1;110(11):2576-86
references.pmid: 17941006
references.citation: Ann Oncol. 2005 Oct;16(10):1683-7
references.pmid: 16093276
references.citation: J Clin Oncol. 2005 Aug 1;23(22):5052-60
references.pmid: 15955904
references.citation: Lancet. 2002 Jun 15;359(9323):2065-71
references.pmid: 12086759
references.citation: N Engl J Med. 2007 Nov 8;357(19):1916-27
references.pmid: 17989384
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3128-35
references.pmid: 16754934
references.citation: Lancet Oncol. 2004 Jan;5(1):19-26
references.pmid: 14700605
references.citation: Lancet. 1993 Apr 24;341(8852):1051-4
references.pmid: 8096958
references.citation: Leuk Lymphoma. 2005 Nov;46(11):1561-7
references.pmid: 16236610
references.citation: J Clin Oncol. 2010 Sep 20;28(27):4199-206
references.pmid: 20713848
references.citation: Ann Oncol. 2002 Oct;13(10):1628-35
references.pmid: 12377653
references.citation: Curr Hematol Malig Rep. 2011 Sep;6(3):172-9
references.pmid: 21567226
references.citation: Bone Marrow Transplant. 2011 Jun;46(6):847-51
references.pmid: 20856212
references.citation: Lancet. 2012 May 12;379(9828):1791-9
references.pmid: 22480758
references.citation: N Engl J Med. 2010 Aug 12;363(7):640-52
references.pmid: 20818855
references.citation: J Clin Oncol. 2011 Nov 10;29(32):4234-42
references.pmid: 21990399
references.citation: Ann Oncol. 2008 Oct;19(10):1754-8
references.pmid: 18467315
references.citation: J Clin Oncol. 2009 Sep 20;27(27):4605-12
references.pmid: 19687337
references.citation: Cochrane Database Syst Rev. 2011 Aug 10;(8):CD007941
references.pmid: 21833963
references.citation: Blood. 2010 Dec 2;116(23):4934-7
references.pmid: 20733154
references.citation: Dtsch Arztebl Int. 2012 Jan;109(1-2):8-13
references.pmid: 22282711
references.citation: J Clin Oncol. 2001 Dec 1;19(23):4314-21
references.pmid: 11731514
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3495-502
references.pmid: 17606976
references.citation: J Clin Oncol. 2008 Dec 20;26(36):5980-7
references.pmid: 19018090
references.citation: J Clin Oncol. 2011 Apr 20;29(12):1607-11
references.pmid: 21402606
references.citation: Br J Cancer. 2003 Aug 4;89(3):482-6
references.pmid: 12888816
references.citation: Leuk Lymphoma. 2009 Nov;50(11):1750-2
references.pmid: 19863179